Marco Basso

Dr. Marco Basso

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GBGiulia Bega
Giulia Bega
JOJacopo Olivieri
Jacopo Olivieri
MRMarcello Riva
Marcello Riva
GSGreta Scapinello
Greta Scapinello
RPRossella Paolini
Rossella Paolini
CVCarlo Visco
Carlo Visco
Background: Rituximab plus bendamustine (BR), and rituximab, bendamustine, and cytarabine (R-BAC) are well-known induction therapies in elderly patients with mantle cell lymphoma (MCL), according to clinical guidelines. However, a direct comparison between the two regimens has never been performed. Methods: In this multicentre retrospective study, we compared the outcome of patients with newly diagnosed MCL, treated with BR or R-BAC. Primary endpoint was 2-year progression-free survival (PFS). Inclusion bias was assessed using a propensity score stratified by gender, age, MCL morphology, and MIPI score. Results: After adjusting by propensity score, we identified 156 patients (53 BR, 103 R-BAC) with median age of 72 (53–90). Median follow-up was 46 months (range 12–133). R-BAC was administered in a 2-day schedule or with attenuated dose in 51% of patients. Patients treated with R-BAC achieved CR in 91% of cases, as compared with 60% for BR (p < 0.0001). The 2-year PFS was 87 ± 3% and 64 ± 7% for R-BAC and BR, respectively (p = 0.001). In terms of toxicity, R-BAC was associated with significantly more pronounced grade 3–4 thrombocytopenia than BR (50% vs. 17%). Conclusions: This study indicates that R-BAC, even when administered with judiciously attenuated doses, is associated with significantly prolonged 2-year PFS than BR in elderly patients with previously untreated MCL.

9 December 2022 in Bulletin of Environmental Contamination and Toxicology
Verified
Journal Article
Closed access
PDF file
Marco PiconeMarco Picone
Marco Picone
GDGABRIELE Giuseppe Distefano
GABRIELE Giuseppe Distefano
GBGodbless Adu Benhene
Godbless Adu Benhene
Fabiana CoramiFabiana Corami
Fabiana Corami
MBMarco Basso
Marco Basso
AGAnnamaria Volpi Ghirardini
Annamaria Volpi Ghirardini

11 March 2026 in ESMO Open
Verified
Journal Article
Open access
Francesca GayFrancesca Gay
Francesca Gay
GBG. Buda
G. Buda
MPM.T. Petrucci
M.T. Petrucci
NBNiccolò Bolli
Niccolò Bolli
MCM. Cea
M. Cea
Elena ZamagniElena Zamagni
Elena Zamagni
The treatment landscape of multiple myeloma (MM) has been revolutionized over the past two decades, leading to unprecedented deep and durable responses, prolonged survival, and improved quality of life. Nonetheless, MM is still an incurable disease, and many patients, especially those with high-risk cytogenetics, renal impairment, or early drug resistance, continue to face poor outcomes. Selinexor, the first-in-class, orally bioavailable selective inhibitor of exportin 1 (XPO1), has shown encouraging results in combination with other agents, and selinexor-based therapy has been approved for the treatment of relapsed/refractory MM, with selinexor-bortezomib-dexamethasone approved for patients with at least one prior line of therapy and selinexor-dexamethasone approved in the later-relapse setting. Notably, selinexor-based combinations have demonstrated consistent efficacy across different subgroups of patients, including those with triple-class refractory disease, renal dysfunction, high-risk cytogenetics, and prior anti-CD38 therapy. We herein provide an overview of selinexor, by describing its mechanism of action, potential interaction with other classes of drugs, novel combinations under investigation, and its role in treatment sequencing, by discussing latest results and potential strategies to mitigate toxicities, increase efficacy, and implement treatment adherence in MM. Overall, selinexor continues to represent a valuable option, especially for patients who are ineligible to receive T-cell-redirecting therapies, or difficult-to-treat patient subgroups, where alternative strategies remain limited. Meanwhile, further data on the use of selinexor-based combinations in different settings are eagerly awaited, to help clarify its role and address persistent unmet clinical needs.

9 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MGMichele Gottardi
Michele Gottardi
FMFederico De Marchi
Federico De Marchi
GCGiulia Ciotti
Giulia Ciotti
MBMarco Basso
Marco Basso
Vittoria RaimondiVittoria Raimondi
Vittoria Raimondi
ASAlessandra Sperotto
Alessandra Sperotto
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem-cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.

27 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MGMichele Gottardi
Michele Gottardi
FMFederico De Marchi
Federico De Marchi
GCGiulia Ciotti
Giulia Ciotti
MBMarco Basso
Marco Basso
Vittoria RaimondiVittoria Raimondi
Vittoria Raimondi
ASAlessandra Sperotto
Alessandra Sperotto
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.

29 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ASAlessandra Sperotto
Alessandra Sperotto
FMFederico De Marchi
Federico De Marchi
MBMarco Basso
Marco Basso
GCGiulia Ciotti
Giulia Ciotti
AAAlessandro Atanasio
Alessandro Atanasio
MGMichele Gottardi
Michele Gottardi
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This narrative review, searched from Pubmed, from 2015 to 2026, critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, and treatment initiation and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.